Federal Circuit Upholds Decision Favoring Amgen’s Biosimilar in Patent Dispute with Regeneron

The Federal Circuit has upheld a lower court’s decision not to issue a preliminary injunction blocking Amgen’s biosimilar version of Regeneron’s Eylea, an eye medication that has gained prominence in the pharmaceutical market. This decision comes as part of a patent infringement lawsuit where the court’s application of claim construction precedent was upheld. This legal affirmation marks a significant step for Amgen in the ongoing litigation regarding the biosimilar’s market entry and underscores the evolving landscape of patent law in the biotechnology sector. Further details on the court’s decision and its implications can be explored here.